amylase alpha 1C

Overview

Amylase alpha 1C (AMY1C) is a member of the amylase family of enzymes, which play a crucial role in carbohydrate metabolism by catalyzing the hydrolysis of starch into sugars. This enzyme is primarily produced in the salivary glands and pancreas, contributing to the digestion of carbohydrates in the human body. The activity of AMY1C is significant in the context of metabolic diseases, particularly type 2 diabetes, where the regulation of carbohydrate absorption is critical. Inhibiting AMY1C can slow down the digestion of carbohydrates, thereby reducing postprandial blood glucose levels, which is a therapeutic target for managing diabetes.

Focus of Latest Publications

Recent studies have extensively investigated inhibition of α-amylase as a therapeutic approach for managing glucose metabolism and obesity-related metabolic dysfunction. A diverse array of compounds have demonstrated inhibitory activity against this enzyme, including natural plant-derived polyphenols such as proanthocyanidins from cranberry extract, phenolic compounds from Fagonia cretica and hawthorn leaves, and essential oils from Boswellia serrata, as well as engineered nanoparticle systems—including zinc oxide nanoparticles synthesized from pomegranate husk extract and ascorbic acid-functionalized zinc oxide nanoparticles (ZnO-AA NPs). Additionally, novel synthetic compounds (triazole oxime derivatives and bismuth-based hybrid materials) and selenized polysaccharide nanoparticles have demonstrated potent inhibitory capacity, with several outperforming the reference antidiabetic drug acarbose in direct comparisons.

The principal mechanism of action across these studies involves delaying intestinal carbohydrate digestion and glucose absorption. Proanthocyanidin-rich cranberry extract improved glycemia and glucose tolerance in established diet-induced obesity through α-amylase inhibition coupled with selective remodeling of the gut microbiota, particularly expansion of Akkermansia muciniphila. Nanoparticle formulations demonstrated enhanced inhibitory efficacy relative to free compounds through improved cellular uptake and bioavailability; selenized polysaccharide nanoparticles achieved glycemic control equivalent to substantially higher doses of the unconjugated compound in streptozotocin-induced diabetic mice. Molecular docking studies identified specific phytochemical constituents—quercetin, luteolin, catechin, gallic acid, and trans-caffeic acid—as primary mediators of α-amylase binding, with binding affinities frequently exceeding reference inhibitors.

The α-amylase inhibitory effects observed across these structurally diverse compound classes—natural polyphenols, synthetic molecules, and nanoparticulate systems—consistently correlated with broader antioxidant activity and improved metabolic parameters. Extraction methodology and plant organ source significantly influenced inhibitory potency, reflecting compositional variation in bioactive phenolics and flavonoids. These findings position α-amylase inhibition as a validated and multifunctional therapeutic target applicable to natural product-based therapeutics, nanotechnology-enabled drug delivery, and synthetic molecular design for addressing type 2 diabetes and obesity-associated complications.